Need Help?

RNA-sequencing data of post-mortem brain tissue taken from individuals with SCA3 and controls

Spinocerebellar ataxia type 3 (SCA3) is the most common autosomal dominant inherited ataxia worldwide, caused by a CAG repeat expansion in the Ataxin-3 gene resulting in a polyglutamine (polyQ)-expansion in the corresponding protein. Here we have RNA-sequencing data from the cerebellum of individuals with SCA3 and matched controls.

Request Access

This is the data access policy for the human RNA-sequencing data associated with the study:A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes

1. The User Institution agrees to only use this data for academic research purposes. 2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. 3. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction. 5. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data. 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data. 7. The User Institution agrees to follow the Fort Lauderdale Guidelines (http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf ) and the Toronto Statement (http://www.nature.com/nature/journal/v461/n7261/full/461168a.html). This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data. 8. The User Institution agrees to follow the Publication Policy; In any publications based on these data, please describe how the data can be accessed, including the name of the hosting database (e.g., The European Genome-phenome Archive at the European Bioinformatics Institute) and its accession numbers, please also cite the original paper for which this data was generated for. 9. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 10. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) (https://www.icgc.org/files/daco/NIH_BestPracticesLicensingGenomicInventions_2005_en.pdf ) in conformity with the Organisation for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) (http://www.oecd.org/science/biotech/36198812.pdf ). 11. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements. 12. The User Institution will notify the DAC within 30 days of any changes or departures of Authorised Personnel. 13. The User Institution will notify the DAC prior to any significant changes to the protocol for the Project. 14. The User Institution will notify the DAC as soon as it becomes aware of a breach of the terms or conditions of this agreement. 15. The DAC may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements. 16. The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. As an example, this may include specific provisions relating to the Data required by Data Producers other than James D. Mills and Eleonora Aronica. In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement. 17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement. 18. The User Institution agrees to distribute a copy of these terms to the Authorised Personnel. The User Institution will procure that the Authorised Personnel comply with the terms of this agreement. 19. This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of the Netherlands and shall be subject to the exclusive jurisdiction of the Netherlands courts.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00006952505 1662030921288 498.4 MB
EGAF00006952506 1662030921288 518.7 MB
EGAF00006952507 1662030921288 496.5 MB
EGAF00006952508 1662030921288 516.4 MB
EGAF00006952509 1662030921288 221.5 MB
EGAF00006952510 1662030921288 232.0 MB
EGAF00006952511 1662030921288 1.8 GB
EGAF00006952512 1662030921288 1.8 GB
EGAF00006952513 1662030921288 1.8 GB
EGAF00006952514 1662030921288 1.8 GB
EGAF00006952515 1662030921288 781.4 MB
EGAF00006952516 1662030921288 822.9 MB
EGAF00006952517 1662030921288 1.4 GB
EGAF00006952518 1662030921288 1.5 GB
EGAF00006952519 1662030921288 1.4 GB
EGAF00006952520 1662030921288 1.5 GB
EGAF00006952521 1662030921288 630.1 MB
EGAF00006952522 1662030921288 664.8 MB
EGAF00006952523 1662030921288 862.3 MB
EGAF00006952524 1662030921288 905.7 MB
EGAF00006952525 1662030921288 859.7 MB
EGAF00006952526 1662030921288 902.4 MB
EGAF00006952527 1662030921288 377.8 MB
EGAF00006952528 1662030921288 399.4 MB
EGAF00006952529 1662030921288 1.4 GB
EGAF00006952530 1662030921288 1.4 GB
EGAF00006952531 1662030921288 1.4 GB
EGAF00006952532 1662030921288 1.4 GB
EGAF00006952533 1662030921288 603.3 MB
EGAF00006952534 1662030921288 635.0 MB
EGAF00006952535 1662030921288 1.6 GB
EGAF00006952536 1662030921288 1.7 GB
EGAF00006952537 1662030921288 1.6 GB
EGAF00006952538 1662030921288 1.7 GB
EGAF00006952539 1662030921288 721.8 MB
EGAF00006952540 1662030921288 764.2 MB
EGAF00006952541 1662030921288 1.2 GB
EGAF00006952542 1662030921288 1.2 GB
EGAF00006952543 1662030921288 1.2 GB
EGAF00006952544 1662030921288 1.2 GB
EGAF00006952545 1662030921288 516.2 MB
EGAF00006952546 1662030921288 541.4 MB
EGAF00006952547 1662030921288 612.0 MB
EGAF00006952548 1662030921288 636.3 MB
EGAF00006952549 1662030921288 610.2 MB
EGAF00006952550 1662030921288 634.0 MB
EGAF00006952551 1662030921288 272.8 MB
EGAF00006952552 1662030921288 285.4 MB
EGAF00006952553 1662030921288 666.8 MB
EGAF00006952554 1662030921288 696.5 MB
EGAF00006952555 1662030921288 664.9 MB
EGAF00006952556 1662030921288 694.2 MB
EGAF00006952557 1662030921288 290.3 MB
EGAF00006952558 1662030921288 305.8 MB
EGAF00006952559 1662030921288 942.0 MB
EGAF00006952560 1662030921288 982.7 MB
EGAF00006952561 1662030921288 939.0 MB
EGAF00006952562 1662030921288 979.2 MB
EGAF00006952563 1662030921288 413.4 MB
EGAF00006952564 1662030921288 434.5 MB
EGAF00006952565 1662030921288 1.2 GB
EGAF00006952566 1662030921288 1.3 GB
EGAF00006952567 1662030921288 1.2 GB
EGAF00006952568 1662030921288 1.3 GB
EGAF00006952569 1662030921288 547.0 MB
EGAF00006952570 1662030921288 574.9 MB
EGAF00006952571 1662030921288 1.9 GB
EGAF00006952572 1662030921288 2.0 GB
EGAF00006952573 1662030921288 1.9 GB
EGAF00006952574 1662030921288 2.0 GB
EGAF00006952575 1662030921288 853.7 MB
EGAF00006952576 1662030921288 902.7 MB
72 Files (70.5 GB)